In practice since 1985, Victor L. Roberts, MD, is the founder of Endocrine Associates of Florida in Lake Mary. Victor L. Roberts, MD, is an expert on the use of empagliflozin to control type 2 diabetes.
Approved by the FDA in 2014, the medication controls blood sugar and is prescribed for adults in conjunction with exercise and diet. Known to consumers as Jardiance, empagliflozin also consistently reduces the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. Cardiovascular disease is two to four times more common in people with type 2 diabetes and encompasses several different vascular outcomes, including heart attack, heart failure, peripheral vascular disease and stroke. In the landmark EMPEROR-Preserved® phase III trial, Jardiance reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline. Jardiance consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m2 regardless of chronic kidney disease status at baseline. Manufactured as a tablet, its recommended starting dose is 10 mg, taken once a day in the morning. The dosage can be increased to 25 mg, if necessary. Not recommended for type 1 diabetes, empagliflozin is also contraindicated for patients in their second or third trimester of pregnancy ( should be carefully considered before use in the first trimester of pregnancy), as well as avoid in those patients on dialysis or with end-stage renal disease. Offsetting empagliflozin’s benefits are potential side effects, including bladder pain, cloudy, painful, or bloody urine, changes in vaginal discharges, and painful intercourse. Usage may also result in frequent urination or back and side pain.
0 Comments
An accomplished endocrinologist, Victor L. Roberts, MD, has served as the clinical and administrative head of Endocrine Associates of Florida since 1988. He also has a long history of involvement with the American Diabetes Association (ADA). Among his other work with the ADA, Victor L. Roberts, MD, has sat on the organization’s National Board of Directors and served as president of its South Coastal Region.
A massive organization of over 565,000 volunteers and nearly 20,000 healthcare professionals, the ADA spearheads extensive diabetes research and direct patient support initiatives. It also strives to prevent and mitigate diabetes by promoting healthy living. Recognizing that proper nutrition is essential for healthy living, the ADA has developed the Diabetes Plate Method. Beyond helping people with diabetes manage their blood sugar levels, the Diabetes Plate Method can help anyone who wants to eat well-balanced meals. The Diabetes Plate Method is designed to be incredibly easy, allowing people to eat a healthy mix of carbohydrates, protein, and vegetables without counting calories, calculating proportions, or measuring servings. It works by mentally dividing a single plate into various sections and then filling half the plate with non-starchy vegetables. Splitting the remaining half of the plate into quarter sections, diners can fill those sections with lean protein and carbohydrates. For more than three decades, Victor L. Roberts, MD, has treated patients as the founding president and chief executive officer of Endocrine Associates of Florida, PA, in Lake Mary. He specializes in helping patients treat and manage diabetes and other endocrine diseases. In his work, Victor L. Roberts, MD, advocates for the use of continuous glucose monitoring in the management of diabetes.
Continuous glucose monitoring (CGM) is a technology that can greatly benefit those with diabetes. Essentially, a CGM device monitors a person’s blood sugar around the clock, constantly checking blood sugar levels. This ongoing monitoring gives those with diabetes a clear understanding of how various factors—like food intake, medication, and activities—affect blood sugar levels throughout the day. One major benefit of CGM technology is that it can HELP TO prevent severe low blood sugar events, also known as hypoglycemic episodes, BY ALERTING THE PATIENT TO AN ABRUPT DROP IN GLUCOSE. The technology can also HELP TO prevent blood sugar spikes, WITH PROMPT ALERTS TO CHANGES IN GLUCOSE. Reducing the number of high blood sugar episodes helps prevent various diabetes complications, including heart and kidney disease, problems with eyesight, and nerve issues. Overall, CGM devices can help bring down HbA1c levels, an important measure of long-term blood sugar control. Along with supporting better blood sugar control, CGM technology empowers those with diabetes by providing valuable insights into how everyday decisions affect their condition. Knowing how glucose levels change over time can assist people in making smarter choices about what they eat, when and how much they exercise, and how much medication they need. This ensures that managing one’s diabetes is less about guesswork and more about informed decisions. Victor L. Roberts, MD, is the president and chief executive officer of Endocrine Associates of Florida in Lake Mary. During his career in endocrinology, Victor L. Roberts, MD, has become an advocate for continuous glucose monitoring.
Continuous glucose monitoring (CGM) is a process or technology that allows an individual to consistently and automatically track glucose levels in the blood, more commonly referred to as their blood sugar level. CGM is particularly beneficial for individuals living with diabetes on multidose insulin therapy or an insulin pump, as it provides real-time blood sugar information at a glance. In addition to checking a person’s glucose levels at any given time, individuals and medical professionals can use CGM to analyze levels over a longer period of time, identifying trends and patterns. This allows a person to make more informed decisions about their diet, exercise and medication. It can also help evaluate the effectiveness or any unforeseen complications of a new medication. Most CGM devices function as small sensors placed just below the skin, on the abdomen or arm. Individuals who believe they could benefit from CGM technology should speak with their physicians. Victor L. Roberts, MD, has served as the president, chief executive officer, and founding partner of Endocrine Associates of Florida, PA, in Lake Mary since establishing the business in 1988. Over the course of his career in medicine, Victor L. Roberts, MD, has become a vocal advocate for ongoing glucose monitoring for diabetes management.
Individuals living with diabetes may benefit from a device known as a continuous glucose monitor (CGM). These devices have been developed as tools to help people living with diabetes track their blood sugar levels. A CGM that has been approved by the United States Food and Drug Administration will provide users with accurate blood sugar levels every 5 to 15 minutes. Users can set their devices to report findings after a certain interval of time. In addition to alerting individuals regarding blood sugar emergencies with an audible alarm, CGMs can help them identify trends and patterns in the way their blood sugar levels ebb and flow. There are several types of CGMs, including devices designed for children. Patients typically require a doctor’s prescription to acquire a CGM. CGMs detect blood sugar levels through the use of small sensors. These sensors may be inserted under the skin in a quick, painless procedure or fixed to the back of the user’s arm. Any person living with diabetes who feels they may benefit from the use of a CGM should discuss the device with a physician. 8/4/2022 0 Comments Continuous Glucose MonitorsA board-certified endocrinologist who draws upon three decades of medical experience, Victor L. Roberts, MD, manages his private practice, Endocrine Associates of Florida, which he established in 1988. Victor L. Roberts, MD, cares for patients with diabetes, which requires continuous glucose monitoring.
Continuous glucose monitors (CGMs) are devices that help measure blood glucose levels (blood sugar) automatically and provide real-time readings on connected devices. A continuous glucose monitor (CGM) is essentially a sensor. The sensor is implanted under the skin in the arm or abdomen. After it is placed, the CGM tests interstitial (between cells) glucose and wirelessly relays data to a special monitor device, a tablet, or smartphone. CGMs have evolved over the years. Since these devices help guide diabetic patients or their guardians make informed decisions regarding meals, exercise, and other activities to keep blood sugar in check, they can be even more effective if they can alert individuals when there are abrupt and potentially detrimental changes in readings. For this reason, some manufacturers are rolling out models that include this function. Some CGMs sound alarms when they read glucose levels that are too low or too high. Many CGMs also alert parents when their child's blood sugar indicates a red flag. An experienced endocrinologist, Victor L. Roberts, MD, has operated Lake Mary’s Endocrine Associates of Florida since 1988. Victor L. Roberts, MD, is a staunch advocate for gliflozins in the management of diabetes with the extra advantage of assisting with cardiac disease
Clinically known as “sodium-glucose co-transporter-2” or “SGLT2” inhibitors, gliflozins have proven useful in the treatment of type 2 diabetes for roughly two decades. They function by boosting the natural ability of the kidneys to lower glucose levels in the bloodstream. Today, a growing number of clinical specialists are advocating for the management of gliflozins in patients with heart failure and other cardiovascular issues. For example, on May 26, 2022, the New England Journal of Medicine published the article “Gliflozins in the Management of Cardiovascular Disease” by Eugene Braunwald. This article recognizes the ability of gliflozins to lower blood glucose without causing hypoglycemia. It concludes that gliflozins can safely increase cardiac function in heart failure patients regardless of any type 2 diabetes diagnosis. Victor L. Roberts, MD, oversees all aspects of patient care and office operations as a primary provider and head administrator of Endocrine Associates of Florida in Lake Mary. Victor L. Roberts, MD, also has a history of publication in peer-reviewed journals, including Clinical Therapeutics and Endocrine Practice.
In 2009, he joined with five colleagues in publishing “Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea” in Current Medical Research and Opinion. This frequently cited article established biphasic insulin aspart 70/30 (BIAsp 30) as an attractive alternative to exenatide. These two medications are prescription treatments for type 2 diabetes. The article ultimately concludes that type 2 diabetes patients who have been unable to control their condition with a combination of metformin and sulfonylurea treatment are more likely to hit glycemic goals under BIAsp 30 treatment. Although they might experience minor hypoglycemic events and weight gain, BIAsp 30 patients report fewer and less severe gastrointestinal side-effects than exenatide patients do. Based in Lake Mary, Victor L. Roberts, MD, serves as president and chief executive officer with Endocrine Associates of Florida. A founding partner, he is also dedicated to full-time patient care. As a physician, Victor L. Roberts, MD, has closely followed developments in the COVID-19 pandemic.
The COVID-19 pandemic has impacted virtually every aspect of life in recent years. That said, individuals may still be unaware of exactly what the coronavirus is. To begin, it can be helpful to clarify the basic terminology. Coronaviruses are a virus family consisting of many distinct viruses, while COVID-19 is a disease caused by the SARS-CoV-2 virus that began the global pandemic in December 2019. Common symptoms of the disease include, but are not limited to, a cough, a sore throat, difficulty breathing, and a loss of taste or smell. Based on the name SARS-CoV-2, individuals may wonder whether the virus is similar to SARS, an acute respiratory syndrome that impacted the United States and other nations in 2003. Indeed, the two pathogens share many similarities, though the current strain is capable of faster transmissions over greater distances compared to the 2003 SARS-CoV-1 virus. It must be noted that the SARS-CoV-2 virus has already mutated into various strains, including the B.1.1.7 and B.1.351 variants. Mutations allow the disease to continue spreading at an accelerated rate, which in turn increases the chances of further mutations and variant strains. To learn more about how the virus spreads and steps that can be taken to reduce the chances of becoming ill, including the importance of vaccinations, individuals should discuss coronaviruses and the COVID-19 disease with a trusted medical professional. As a professor of internal medicine at the University of Central Florida school of medicine and president of Endocrine Associates of Florida, Victor L Roberts, MD, is experienced in the field of endocrinology. In 1988 he established Endocrine Associates of Florida, which continues to provide specialized treatment for diabetes, thyroid disorders, and other metabolic-related diseases. Prioritizing the safety and well-being of staff and patients, Victor L Roberts, MD, and his associates strictly follow COVID-19 protocols for maintaining a safe environment for patients and staff.
In an effort to provide excellent medical care, Endocrine Associates of Florida maintains precautionary measures for ensuring the well-being of their patients. Surfaces are disinfected after every patient visit to deter transmission of the virus that causes COVID-19. Temperatures are taken at check-in and hand sanitizer is available throughout the office areas. Additionally, patients are required to wear masks and maintain the recommended physical distance from each other. These practices allow staff to perform their duties and ensure a safe environment for patients. |
AuthorDr. Victor Roberts Archives
September 2021
CategoriesAll Community Outreach Covid-19 Cushing’s Syndrome Diabetes Health Hormonal Causes Hypothyroidism Urination Victor L Roberts MD |